Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Neuralstem has entered into a clinical trial research agreement aimed at treating patients suffering from ischemic spastic paraplegia, a form of spinal cord paralysis, with the trustees of the University of Pennsylvania through its department of anesthesiology and critical care.
Subscribe to our email newsletter
The institution’s principal investigator is Albert Cheung, department of anesthesiology, Hospital of the University of Pennsylvania.
Ischemic spastic paraplegia is a painful form of extreme spasticity and rigidity that causes permanent and untreatable loss of motor function and paralysis.
Richard Garr, Neuralstem’s president, said: “We are extremely pleased to be partnering with the University of Pennsylvania Hospital, and Dr Cheung’s team on this important milestone. They bring world-class experience and talent across the many disciplines that are required for moving into the clinic for our first human trial.”
Dr Cheung said: “We at Penn are deeply committed to finding a way to help these patients, and we are excited to be working with Neuralstem’s cutting-edge technology.”